Granules India

Expanding API Capacity And Aging Global Population Will Fuel Opportunity

AnalystHighTarget

Not Invested

Consensus Narrative from 7 Analysts

Published

24 Aug 25

Updated

24 Aug 25

AnalystHighTarget's Fair Value

₹700.00

32.9% undervalued

24 Aug

₹469.55

-30.3%

2.8%

-30.3%

2.8%

Author's Valuation

₹700.0

32.9% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

₹700.0

32.9% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

14.35%

Pharma revenue growth rate

0.58%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

12.73%

Calculation

₹9.42b

Earnings '28

25.87x

PE Ratio '28

₹243.67b

Market Cap '28

₹243.67b

Market Cap '28

243.57m

No. shares '28

₹1.00k

Share Price '28

₹1.00k Share Price '28

Discounted to 2025 @ 12.73% p.a.

₹698.38

Fair Value '25